[1]
Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and control of diabetes in the United States 1988-1994 and 1999-2010. Ann Intern Med 2014; 160: 512-25.
[2]
Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 2012; 19: 93-6.
[3]
Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
[4]
Zhou B, Lu Y, Hajifathalian K. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387: 1513-30.
[5]
Khan Y, Hamdy O. Type 2 diabetes in the middle east and north africa (MENA). In: Dagogo-Jack, Sam (Ed.)Diabetes mellitus in developing countries and underserved communities. Springer International Publishing 2017; pp. 49-61.
[6]
Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.
[7]
Anselmino M, Mellbin L, Wallander M, et al. Early detection and integration management of dysglycemia in cardiovascular disease: A key factor for decreasing the likelihood of future events. Rev Cardiovasc Med 2008; 9: 29-38.
[8]
Arnold SV, Lipska KJ, Li Y, et al. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. Am Heart J 2014; 168: 466-70.
[9]
Chen PC, Chua SK, Hung HF, et al. Admission hyperglycemia predicts poorer short- and long-term outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Diabetes Investig 2014; 5: 80-6.
[10]
Kuramitsu S, Yokoi H, Domei T, et al. Impact of post-challenge hyperglycemia on clinical outcomes in Japanese patients with stable angina undergoing percutaneous coronary intervention. Cardiovasc Diabetol 2013; 12: 74.
[11]
Lee TF, Burt MG, Heilbronn LK, et al. Relative hyperglycemia is associated with complications following an acute myocardial infarction: A post-hoc analysis of HI-5 data. Cardiovasc Diabetol 2017; 16: 157.
[12]
Donahoe SM, Steward GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndrome. JAMA 2007; 298: 765-75.
[13]
Aggarwal B, Shah GK, Randhawa M, et al. Utility of glycated hemoglobin for assessment of glucose metabolism in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2016; 117: 749-53.
[14]
Kim EJ, Jeong MH, Kim JH, et al. Clinical impact of admission hyperglycemia on in-hospital mortality in acute myocardial infarction patients. Int J Cardiol 2017; 236: 9-15.
[15]
Gholap NN, Achana FA, Davies MJ, et al. Long‐term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta‐analysis of studies in the post‐reperfusion era. Diabetes Obes Metab 2017; 19: 364-74.
[16]
Cubbon RM, Abbas A, Wheatcroft SB, et al. Diabetes mellitus and mortality after acute coronary syndrome as a first or recurrent cardiovascular event. PLoS One 2008; 3e3483
[17]
Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome. A scientific statement from the American heart association diabetes committee of the council on nutrition, physical activity, and metabolism. Circulation 2008; 117: 1610-9.
[18]
Arnold SV, Lipska KJ, Inzucchi SE, et al. The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. BMJ Open Diabetes Res Care 2014; 2e000046
[19]
Colombo MG, Meisinger C, Amann U, et al. Association of obesity and long-term mortality in patients with acute myocardial infarction with and without diabetes mellitus: results from the MONICA/KORA myocardial infarction registry. Cardiovasc Diabetol 2015; 14: 24.
[20]
Zubaid M, Thani KB, Rashed W, et al. Design and rationale of Gulf locals with acute coronary syndrome events (Gulf Coast) registry. Open Cardiovasc Med J 2014; 8: 88-93.
[21]
Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in US diabetes care, 1999-2010. N Engl J Med 2013; 368: 1613-24.
[22]
Al-Rasadi K, Al-Zakwani I, Alsheikh-Ali AA, et al. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol 2018; 12: 685-92.
[23]
Khesroh AA, Al-Roumi F, Al-Zakwani I, et al. Gender differences among patients with acute coronary syndrome in the Middle East. Heart Views 2017; 18: 77.
[24]
Zubaid M, Rashed W, Alsheikh-Ali AA, et al. Disparity in ST-segment elevation myocardial infarction practices and outcomes in Arabian Gulf countries (Gulf COAST Registry). Heart Views 2017; 18: 41.
[25]
Shore S, Borgerding JA, Gylys-Colwell I, et al. Association between hyperglycemia at admission during hospitalization for acute myocardial infarction and subsequent diabetes: Insights from the veterans administration cardiac care follow-up clinical study. Diabetes Care 2014; 37: 409-18.
[26]
Beck JA, Mesinger C, Heier M, et al. Effect of blood glucose concentration on admission in non-diabetic versus diabetic patients with first acute myocardial infarction on short-and long-term mortality (from the MONICA/KORA Augsburg myocardial infarction registry). Am J Cardiol 2009; 109: 1607-12.
[27]
Karamat MA, Raja UY, Manley SE, et al. Prevalence of undiagnosed type 2 diabetes in patients admitted with acute coronary syndrome: The utility of easily reproducible screening methods. BMC Endocr Disord 2017; 17: 3.
[28]
Stolker JM, Spertus JA, McGuire DK, et al. Relationship between glycosylated hemoglobin assessment and glucose therapy intensification in patients with diabetes hospitalized for acute myocardial infarction. Diabetes Care 2012; 35: 991-3.
[29]
Ritsinger V, Malmberg K, Mårtensson A, et al. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20-year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol 2014; 2: 627-33.
[30]
Zhao S, Murugiah K, Li Na, et al. Admission glucose and in-hospital mortality after acute myocardial infarction in patients with or without diabetes: A cross-sectional study. Chin Med J (Engl) 2017; 130: 767-75.
[31]
Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction. Circulation 2005; 111: 3078-86.
[32]
Wei CC, Shyu KG, Cheng JJ, et al. Diabetes and adverse cardiovascular outcomes in patients with acute coronary syndrome-data from Taiwan’s acute coronary syndrome full spectrum data registry. Acta Cardiol Sin 2016; 32: 31-8.
[33]
Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol 2018; 3: 280-7.
[34]
Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive insulin infusion in infarction (HI-5) study: A randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006; 29: 765-70.
[35]
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247-57.
[36]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-22.
[37]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
[38]
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol 2017; 70: 1785-822.
[39]
Handelsman Y, Lepor NE. PCSK9 Inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: A review. J Am Heart Assoc 2018; 7e008953
[40]
Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: The IMPROVE-IT trial. J Am Coll Cardiol 2016; 67: 353-61.
[41]
Giugliano RP, Keech A, Murphy SA, et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiol 2017; 2: 1385-91.
[42]
Goodman SG, Schwartz G, Bhatt DL, et al. Use of high-intensity statin therapy post-acute coronary syndrome in the ongoing ODYSSEY OUTCOMES trial of alirocumab, a proprotein convertase subtilisin/kexin type 9 monoclonal antibody, versus placebo: Interim baseline data. J Am Coll Cardiol 2017; 69: 153.
[43]
Masmiquel L, Leiter LA, Vidal J, et al. LEADER 5: Prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: Baseline global data from the LEADER trial. Cardiovasc Diabetol 2016; 15: 29.
[44]
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 2016; 37: 1526-34.
[45]
Katsiki N, Purrello F, Tsioufis C, et al. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother 2017; 18: 1243-60.
33
2